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Cocaine abuse is a widespread problem with no effective treatment. Cocaine primarily blocks the 
dopamine transporter’s (DAT) ability to remove dopamine from the synapse, leading to a 
potentiation of dopaminergic neurotransmission. Compounds targeting the dopaminergic system 
have not yielded fruitful results with regard to an effective therapy. Therefore, other receptor 
sites like opioid receptors; glutamate receptors and sigma receptors are being examined. There is 
a great body of evidence that suggests that the dopamine transporters and sigma receptors might 
be working together to bring about cocaine’s effect. Rimcazole is a prominent example of a 
compound with dual activity as a sigma receptor antagonist and a DAT inhibitor that has been 
shown to suppress self-administration as well as the locomotory stimulant effects of cocaine in 
rat models. Interestingly, although sigma ligands can attenuate many of the behavioral effects of 
cocaine, alone they have no effect on cocaine self-administration.  Similarly, DAT inhibitors at 
concentrations that block cocaine self-administration are also self-administered, indicating they 
are simply substitutes for cocaine and the animals are unable to discriminate the compounds.    
Building on our in-house data, we have aimed to synthesize compounds that will have dual 
activity at both these sites and therefore will help suppress cocaine self-administration and 
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DA                                                      dopamine   
DAT                                dopamine transporter 
oC                                   degree Celsius 
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Cocaine abuse remains a serious medical and public health concern worldwide. It is the 
second most commonly used illicit drug (following marijuana) in the United States. According to 
a report by the National Survey on Drug Use and Health (NSDUH) in 2012, it was estimated that 
a population of 1.6 million, aged 12 or older, had used cocaine.1 The two main health hazards 
associated with cocaine consumption are abuse of the drug and the toxicity or lethality due to 
overdose.  
Cocaine (Figure 1) is not a new drug; it is one of the oldest known psychoactive 
substances. However, it was labeled “the drug of the 1980s and 1990s” because of its extensive 
popularity and abuse during that time. Coca leaves, the source of cocaine have been chewed and 
ingested for thousands of years and the purified chemical, cocaine hydrochloride, has been an 
abused substance for more than 100 years.  
However, today it is a Schedule II drug, meaning it is associated with a substantial abuse 
liability and can only be prescribed by physicians for reasonable medical uses like local 
anesthesia for some eye, ear and throat infections.2  
      Pure cocaine was originally extracted from the leaf of the Erythroxylon coca bush, 
growing primarily in Peru and Bolivia. The alkaloid content of coca leaves is low, between 
0.25% and 0.77%.62  Cocaine can be obtained from the coca leaves using a relatively simple 
method by extracting it with an organic solvent resulting in a coca paste containing nearly 80% 
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cocaine. It is generally sold on the street as a fine, white, crystalline powder and is also known as 
“coke”, “C”, “flake” or “blow”.3  
Patterns of its effects and plasma concentrations vary with different routes of  
administration. The primary routes of administration are oral, intranasal, intravenous and 
inhalation. In a single dose, both smoking and intravenous Injections produce extremely high 
rate of absorption (500-1000ng/ml) compared with snorting (100-500ng/ml).4  
Cocaine abuse is associated with substantial social and economic problems with a 
heightened risk of HIV, Hepatitis B and C infections and other diseases. At present there is no 
effective medication available for cocaine addiction, thereby creating an immediate need to 
design and develop new and effective therapies to overcome this serious issue. 
 There are several physiological as well as psychological effects associated with cocaine 
abuse. The psychological manifestations range from euphoria to anxiety, depression and severe 
drug dependence.5 Chronic use of cocaine affects the cardiovascular system, the respiratory 
system as well as the central nervous system. It puts an individual at the risk of hypertension, 
angina pectoris, myocardial infarctions and hemorrhages.6 Cocaine abuse can disrupt the normal 
neuronal circuitry and may even lead to severe seizures in case of overdose.7 
                                                       
Figure 1: Structure of Cocaine 
The “Dopamine Hypothesis” 
Since the last decade there has been enough evidence to support the fact that actions at 
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There is evidence that comes from a microdialysis study, where a probe is put into the 
brain that collected a perfusate that was examined for dopamine concentration, after cocaine 
administration, an increase in the dopamine levels was observed.8  
It is suggested that cocaine mainly inhibits dopamine re-uptake, leading to a potentiation 
of dopaminergic neurotransmission in mesolimbocortical pathways.9 An increase in the 
dopamine concentration in the synapse is what elucidates the pharmacological profile of cocaine.         	  
The early efforts in discovering effective treatment for cocaine abuse basically focused on 
identifying the inhibitors that would block cocaine from getting access to DAT. Therefore several 
analogues were designed and analyzed that would do that, but the majority of them suffered from 
the limitation of having abuse liability like cocaine.40 This has led to a myriad of research being 
carried out towards the discovery of novel strategies for the treatment of cocaine abuse. 
Current Approaches to potential Pharmacotherapies  
1) Targeting DA receptors: 
Because of the link between cocaine’s addictive liability and the DA circuitry, logical 
treatment strategies target the DA system. Dopamine exerts its function by binding to and 
activating the dopamine receptors located on the cell surface.  
In mammals, five subtypes of dopamine receptors have been identified (D1 through D5) 
that all function as G protein-coupled receptors. Dopamine subtypes D1, D2 and D3 are mainly 
thought responsible in the cocaine reinforcement phenomenon. D1 antagonists SCH 2339012 and 
SCH 3916612 and D2 antagonists, eticlopride and spiperone attenuate reinforcing effects of 
cocaine13 (structures in Figure 2).  
BP 897, which acts as a D3 agonist, has shown to inhibits cocaine’s physical dependence 
behavior without causing any reinforcement by itself.14 
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2) Dopamine reuptake inhibitors: 
Direct acting dopamine receptors drugs suffer from the emetic and other side effects 
therefore dopamine reuptake inhibitors are likely to be more effective. Pharmacological studies 
on 1-[2-[bis(4fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909),  N-[1-
(2-benzo(b)thiophenyl)-cyclohexyl]piperidine (BTCP) and methylphenidate (Figure 3) have 
shown that these compounds had great binding affinities at Dopamine transporter and helped 
eliminate cocaine induced drug seeking behavior.15  
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3) Opioid compounds: 
 Opioid receptors (classified as mu, kappa, delta and ORL-1 receptors) are also a 
potential target for cocaine addiction therapy. It has been observed that after the chronic use of 
cocaine, along with the increase in the dopamine concentration, the densities of opioid receptors 
(specifically µ and κ) also increase in the areas in brain (caudate putamen, nucleus accumbens, 
nigrostriatal pathways).16,17 
 Also, compounds such as Naltrexone (opioid antagonist), Buprenorphine(µ-opioid 
agonist) , ethylketocyclazocine, trans-3,4-dichloro- N-methyl- N-[2-(1-pyrrolidinyl)-cyclohexyl]-
benzene acetamide (U-50,488H), Salvinorin A (κ opioid agonists)(Figure 4) have all been shown 
to have effects on cocaine’s addictive potential.18-20  
The opioid like receptor (ORL-1), whose endogenous ligand is Orphanin FQ or 
nociception, shows great homology with traditional opioid receptors is also being implicated in 
the reward properties of cocaine. Administration of OFQ/N in the intracerebroventricular (ICV) 
region of the brain has been shown to attenuate the cocaine-induced CPP in mice.62  
Several studies have shown that targeting both DA and endogenous opiate receptor systems 
can be an effective approach towards the pharmacotherapy for cocaine addiction. 
4) Glutamate receptor antagonists: 
 Studies also show that both ionotropic and metabotropic glutamate receptors (mGluRs) 
are implicated in the behavioral effects of cocaine. Animal relapse models showed that AMPA 
(α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist 6-cyano-7-
nitroquinoxaline-2,3-dione (CNQX) completely inhibited drug seeking behavior in rats.  
 Also, NMDA (The N-methyl-D-aspartate) receptor antagonists like dizocilpine (MK-
801)(Figure 5) blocked cocaines behavioral sensitization.22,23  
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           Figure 5: Glutamate receptor antagonists that block cocaine’s effects 
5) Anti-cocaine vaccines: 
Since there has not yet been an effective cure for cocaine abuse, a new and interesting 
approach of using biologicals such as vaccines, are being developed. These vaccines act as 
“pharmacokinetic” antagonists whereby they stimulate the production of specific antibodies that 
bind to cocaine in the circulating blood and extracellular fluid, slowing down the distribution of 
the drug to brain and thus lowering down the reinforcing effects.38 
Cocaine by itself is not capable of showing an immune response but linking it covalently 
with a carrier protein, gives it hapten like properties thus making it immunogenic. The first 
success was reported by Carrera et al.63 They showed the true blockade of psychostimulant 
effects of cocaine by active immunization, where the cocaine-KLH conjugate GNC-KLH, 
lowered the cocaine levels in brain tissue by 80% and also suppressed locomotor stimulant 
effects of cocaine. 
 Further studies also demonstrated that the antibody titers rose to over 25,000 within three 
injections of 250µg GNC-KLH over a period of five-week immunization. This level of antibody 
suppressed cocaine’s reinstatement response even when three fold of the cocaine dose was 
available. Also, this effect was totally inhibited on the iv administration of the monoclonal anti-
cocaine antibody (mAb) GNC-92H2.64 
The development of the second generation of the cocaine-KLH conjugate termed GND-











	   9	  
The second-generation vaccine showed more advantage over the previous one by offering  
longer term protection against cocaine.  
Another study that tested the anti-cocaine vaccine by the name IP-1010 showed that the 
vaccine antagonized the reinforcing effects of cocaine.66 Along with these success stories with 
the animal studies, one of the vaccines, TA-CD using a cholera B subunit carrier protein was 
reported to be successful in the Phase I and initial Phase II clinical trials.10,11 
Along with all the merits, there are some caveats associated with these vaccines; 
firstly, they won’t work uniformly on cocaine abusers because a quarter of drug abusing 
population has a poor antibody response to existing vaccines. Another challenge appears to be 
those cocaine users who have already “auto-vaccinated” themselves and produced an inhibition 
of high affinity IgG producing cells and instead produce a low affinity IgM.67  
The initial period needs three months of vaccination and co-operation for four-
five vaccines which cocaine abusers might find hard to keep up with. Also, these vaccines are 
not the traditional preventive measures, they do not show the promise to prevent or delay the 
onset of drug abuse.  In conclusion, immune-pharmacotherapy has showed some clinical success 
and appears to be a promising tool to address cocaine abuse but practical challenges limit its 
development. 
Sigma Receptors as targets for Cocaine abuse 
Sigma receptors are now a well-defined class of receptors found distributed in several 
regions of the brain and in the periphery.24They were initially described as a subtype of opioid 
receptors, but this hypothesis got contradicted based on the finding that psychostimulant effects of 
(±)SKF-10,047 and benzomorphans were not reversed by typical opioid receptor antagonists.58 Later 
on , they were classified as N-methyl-D-aspartate receptors, this hypothesis was ruled out when the 
actual NMDA agonists only partially displaced [3H](+)-SKF-10,047.25Sigma receptors were 
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subsequently divided in two classes sigma-1 and sigma-2, both of these have been studied for their 
differences in sizes, distribution in tissues and ligand binding. Sigma-1 has been purified and cloned 
from several species including mouse, rat, guinea pig and human59-63 whereas the protein structure of 
sigma-2, although appears to be a little smaller than sigma-164; it still needs to cloned and elucidated. 
The first evidence of cocaine interacting with the sigma receptors was published in a 1988 
study.26 The actual mechanism of cocaine interaction with sigma receptors is not fully understood, 
but the possibilities are interaction with other neurotransmitter systems, direct binding, modulation 
of receptors, or genetic interactions. Along with the sigma receptor, cocaine seems to interact with 
other neurotransmitter systems as well. It binds with SERT with a Ki value of 1.05 µM and NET 
with Ki of 3.30 µM.27 
Between the two-sigma receptors, cocaine prefers sigma-1 (affinity of 2909 nM as compared 
to 29,175 nM for sigma-2), so it can be concluded that sigma1 is the receptor subtype most likely 
responsible for the physiological and pharmacological profile of cocaine.28 This has also been 
proven by the studies that used specific sigma-1 receptor antagonists and antisense 
oligodeoxynucleotides.29 
Therefore in order to develop an effective therapy against cocaine abuse, targeting sigma-1 
receptor seems to be the logical approach. To accomplish this, effective sigma-1 antagonists that can 
inhibit cocaine binding to the receptor need to be designed. 
Sigma receptor ligands for cocaine abuse 
BD series of compounds 
The ethylenediamine class of compounds (Figure 6) have been shown to exhibit great 
selectivity and affinity for sigma receptors, and have also demonstrated involvement in cocaine 
induced toxicities.30,31 Some of the BD series of compounds that have shown selectivity for sigma-1 
over sigma-2 are listed in Figure 8  . 
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Figure 6: BD series of compounds that have shown selectivity for sigma-1 over sigma-2 
YZ series of compounds  
The aryl-monosubstituted analogs (Figure 7) showed good affinities for sigma receptors with 
particular preference to sigma-1. Their cocaine inhibiting effect resembled to those of antisense 
oligodensenucleotides.32 
UMB series of compounds 
Structural features that made BD and YZ compounds good sigma leads were combined 
together to build the UMB series of compounds.33 (Figure 8) 
In-house efforts 
There has been ongoing in-house effort to design and develop analogues that target the 
various adverse effects of cocaine. It has been established in the literature that blockade of 
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synthetic approach was undertaken to successfully convert selective sigma-1 compounds (having 
a 2(3H)-benzothiazole moiety) to an array of mixed affinity sigma-1 and sigma-2 compounds 
[2(3H)-benzothiazole replaced by a N-cyclohexylpiperazine]. These mixed affinity compounds 
also blocked cocaine-induced convulsions just like their sigma-1 selective counterparts, 
suggesting that sigma-2 receptors might also be involved in cocaine’s activity. Further studies 
are ongoing to better understand sigma-2 receptor’s role in this phenomenon.60                                   
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Figure 8: UMB series of compounds 
In another study, one of our sigma antagonists, CM156 (Figure 9) was able to attenuate 
cocaine induced conditioned place preference.56 Soon after behavioral studies on mouse, their 
brain was collected and studied for alterations in the gene expression through microarray 
technique. As a result, it was observed that cocaine up-regulated four genes. Analysis by real 
time PCR showed that CM156 reversed expression of three (malat1, ywhaz, ttr) out of these four 
genes. Thus it can be inferred that CM156 has the potential to normalize the changes in the 
nervous system, brought about by repeated cocaine exposure.56 In another behavioral study with 
Swiss Webster mice, CM156 showed attenuation of convulsive and locomotor stimulant effects 
of cocaine.57 The limitation associated with CM156 is its rapid rate of metabolism, so metabolic 
studies were conducted and analogues with better pharmacokinetic properties were developed.  
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half-life of AZ66 in was found to be 115 min, which was a significant improvement on its 
predecessor CM156 (5 min). AZ66 displayed high affinity for both the sigma receptor subtypes 
(2.4 nM for sigma-1 and 0.51 nM for sigma-2) and displayed a good pharmacological profile.71 
 
                                             
Figure 9: Structures of CM156 and AZ66 
 
In another study, a synthetic analogue SN79 (6-acetyl-3-(4-(4-(4-fluorophenyl) 
piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one) (Figure 10) showed good affinity for sigma 
receptors.55 Behavioral studies in male Swiss Webster mice showed blockade of convulsive and 
locomotor stimulant effects of cocaine. Oral administration of SN79 showed good bioavailability 
and it did not inhibit major Cytochrome P450 enzymes showing less probability for drug-drug 
interactions. Animals soon showed tolerance to the sedative and motor defects caused by SN79. 
These attributes made SN79 a potential compound for anti-cocaine therapy.58  
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DAT and Sigma receptors as dual targets for cocaine addiction  
Studies have shown that endogenous zinc favors the outward-facing conformation of 
DAT48 and it also been shown to be an endogenous sigma ligand.49Any biological process that 
mobilizes zinc could potentially interact with DAT and sigma receptors50 and might help 
regulate the effects of cocaine.  
Another possible link between sigma receptors and DAT comes from membrane 
cholesterol. Previous studies have documented the involvement of both receptor subtypes in the 
intracellular lipid dynamics.51,52 A recent study confirmed that a cholesterol rich membrane 
environment shifts the DAT equilibrium to the outward facing one.53 
There has also been evidence that show that sigma and D1 receptors heteromerize 
together and that there is the potentiation of D1 regulated adenylyl cyclase by sigma receptors.54 
These studies seem to suggest a potential interaction between sigma and dopaminergic systems 
might be playing a role in the pharmacology of cocaine.  
Rimcazole is one of the known sigma-1 receptor antagonist that also acts as a dopamine 
uptake inhibitor. It has demonstrated blockade of locomotor stimulatory effects produced by 
cocaine.  
Initially thought as an outcome of sigma receptor binding but the discovery of the two-
fold higher affinity for DAT suggested that DAT instead of sigma receptor might be playing a 
role in these actions.34  
Moreover, along with binding to sigma receptors and dopamine transporters, it also showed 
blockade of cocaine self-administration in rats.37 Consistent with this finding, a recent study showed 
that rimcazole binds to DAT in a manner that favors an outward-facing conformation that disallowed 
cocaine binding and contributed to a distinctive behavioral profile.35  
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Rimcazole and analogues36 (Figure11) have shown dose dependent inhibition of cocaine self-
administration without affecting food reinforcement. A series of other sigma antagonists (lacking 
DAT affinity) don’t seem to show this effect across the range that did not alter rates of food 
reinforcement.47 DAT inhibitors like WIN 35,428, methylphenidate and nomifensine themselves 
show self-administration by shifting the cocaine dose response curve leftward.46 When studied alone, 
selective DAT inhibitors and sigma receptor antagonists do not possess rimcazole like blockade of 
self-administration.On the other hand, combinations of WIN 35,428 and other sigma antagonists BD 
1008 and BD 1047 decreased self administration without effects on food maintained responding.50 
This suggests that compounds that can act at both DAT and sigma receptors will have inhibition of 
cocaine self-administration and can thus serve as leads for novel anti-cocaine compounds. 
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The rationale for this project was based on the fact that our selective sigma-1 receptor 
ligand, CM304, combined with either methylphenidate or nomefensine (at doses that had no 
biological activity) blocked cocaine self-administration in rats.  Many of our compounds that 
have already been screened at sigma receptors as well as monoamine transporters (DA, 5-HT, 
NE) were searched thoroughly and our data revealed CM699 (Figure 12) to be a potential 
compound for investigation since it interacted with sigma receptors and had decent affinity for 
DAT (311 nM).  We elected to screen this compound for the cocaine self-administration assay at 
NIDA and it was a success.  The compound blocked cocaine self-administration in rats without 
being self-administered itself or affecting food intake.  This makes it an excellent lead molecule, 
as it is the first of our compounds to do so.  In addition, it binds to sigma-1 and sigma-2 receptors 
but only sigma-1 receptor blockade combined with DAT affinity is actually needed for blocking 
cocaine’s effects.  
                                                    
                                                        CM699 
                                                   Figure 12: Structure of CM699 
 Therefore, in order to improve this lead compound, efforts were made to increase affinity 
and determine the optimal affinity at DAT and to try to increase sigma-1 selectivity, because its 
well understood from studies with sigma-2 selective ligands, that sigma-2 has no effect on 
cocaine self-administration even when combined with sub-therapeutic doses of methylphenidate 
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That is the rationale for trying to find a more optimal ligand.  In addition, CM699 has a 
"short" half-life (4.4 hrs) in the rat and a poor bioavailability so improving the druggability of this 



























The aim of this thesis was to synthesize analogues of CM699 that will have affinity at 
Dopamine transporters and selective affinity for sigma-1 receptors. The synthetic analogues were 
synthesized based on modifications of the linker length between the benzimidazolone and the 
spirobenzisofuran moieties. In an effort to develop selective sigma-1 receptor analogues, we 
focused on the design of novel analogues that can incorporate the features present in the already 
reported sigma-1 selective antagonists. A general template of CM699 was fixed, and spacer 
lengths were modified. Compound 1 (Figure 13) has been reported to have high affinity and 
selectivity for sigma-1 receptors68 has a two-carbon linker between the 2(3H)-bezothiazolone 
moiety and the azepane moiety. Also, BD106369 and AC92770 (Figure 14) have a two-carbon 
linker and are highly selective for sigma-1 over sigma-2.  So, we hypothesized that an analogue 
with two carbon linker between the benzimidazolone and the spirobenzisofuran moieties would 
be more selective for sigma-1 and will have affinity for DAT (as seen for CM699). Also, we 
wanted to test other chain lengths and see their effect on sigma receptor and DAT binding. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Ki,	  σ1	  =	  0.56	  nM	  
	  	  	  	  	  	  	  	  σ2	  =	  >1000	  nM	  
	  	  	  	  	  	  	  σ2/	  σ1	  >	  1785	  





	   20	  
 
Figure14: Structures of sigma-2 selective compounds BD1063 and AC927 
The protocol undertaken to synthesize the analogues: 
1) Synthesize the benzimidazolone precursor 
2) Couple the benzimidazolone with the dibromo alkane 
3) Synthesize the spirobenzisofuran precursor 
4) Couple the alkylated benzimidazolone with the spirobenzisofuran group. 
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Figure 15: Final analogues 
 
The schematic representation of the protocol undertaken to synthesize the analogues: 
 
        
 
































H2/Pd/C , 30 psi
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Scheme 2: The synthesis of spirobenzisofuran precursor was undertaken as outlined here. 
 
                            
Scheme 3: Coupling benzimidazolone with dibromoalkanes 







1) n-BuLi , THF ,  -78 C(30 min)---> rt, 12 h






0 C ---> reflux 12 h
2) HCl , pH-2 reflux 4 h
3) NaOH , pH-10
H2/Pd/C , 50 psi          MeOH
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RESULTS AND DISCUSSION 
The conversion of 1-fluoro-2-nitrobenzene to N-methyl-2-nitroaniline was carried out 
without the presence of methanol as a solvent and took overnight for the reaction to complete at 
95O C, but in case where methanol was used the reaction was complete in half an hour at room 
temperature under reflux conditions. It was a clean reaction, and only gave one spot on TLC. 
This is a classic example of nucleophilic substitution reaction (SN2) whereby in the first step, the 
amine N functions as the nucleophile and attacks the electrophilic C of the 1-fluoro-2-
nitrobenzene displacing the fluoride and creating the new C-N bond. In the subsequent step, an 
acid/base reaction occurs. The base (excess amine) deprotonates the positive N (ammonium) 
center creating the alkylation product, N-methyl-2-nitroaniline. 
 The subsequent production of N1-methylbenzene-1,2-diamine is example of simple 
reduction where an aromatic nitro group can be reduced to the amine by hydrogenation (H2/Pd/C 
in methanol). It was carried out using a Parr hydrogenation apparatus, which ensures a 
continuous pressure of hydrogen. The reaction is conducted in a glass reactor at pressures of 30 
psi, which saves time compared to using hydrogen at atmospheric pressure. 
The caveat associated with this reaction was oxidation, which made the isolation of the 
final product difficult. The presence of both a primary amine and a secondary amine in N1-
methylbenzene-1,2-diamine made it highly susceptible to air oxidation and thus there were 
complex mixtures observed by TLC, making purification difficult and therefore lowering the 
yields. This step was repeated several times and the product was handled carefully to minimize 
air exposure. The first approach that was used to overcome this problem was to use the product 
directly for the next reaction giving the least amount of time to sit idle and form any oxidation 
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byproducts. The solvent was evaporated and then kept under argon and the concentrated product 
was kept under argon until the next reaction was ready to be set up. If the next step could not be 
carried immediately, then the product was converted to a more stable HCl salt. 
     The next step was the production of the benzimidazolone derivative which was carried 
out using N, N'-carbonyldiimidazole (CDI) (Figure 16), a reagent often used as a peptide 
coupling reagent. CDI assists in the acylation of amino compounds and also as a reagent in the 
organic synthesis for the production of ureas and carbamates from amines and alcohols 
respectively. CDI is extremely hygroscopic and thus needed to be stored and used with exclusion 
of moisture. 
 
                                                        
Figure 16: N, N'-Carbonyldiimidazole 
                                                                      
Usually CDI is added in the equimolar concentrations relative to the amine component. 
For this reaction, CDI was used in excess and lead to the production of an isocyanate which was 
trapped by the other amine functionality leading to the formation of the final compound. This 
reaction can be carried out in a variety of anhydrous solvents. Dry THF gave better yields and 
was comparatively faster than dry DCM. Purification using column chromatography is simpler 
and cleaner when carried out in DCM/MeOH as compared to EtOAc/Hex. The mechanism of the 
production of 1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one reaction is well understood. 
CDI undergoes a nucleophilic attack by N1-methylbenzene-1,2-diamine leading to elimination of 
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The next step was alkylation of the benzimidazolone with terminal dibromo alkanes. It is 
a simple example of N-alkylation using alkyl bromides, by an SN2 mechanism.   
The yields of these reactions were poor as the product amines were still nucleophillic and 
reacted with additional halide to give quaternary ammonium by-products which basically were a 
mixture of amines in varying states of alkylation. One of the side products was a dimer where a 
second molecule of benzimidazolone gets alkylated with the second bromine hanging at the tail 
of the initial alkylated product. 
This N-alkylation requires a strong base as a catalyst in stoichiometric amounts. Various 
available bases that can be used are listed as follows:  
• alkali metals 
• alkali metal alkoxides  
• potassium super oxide in crown ethers 
• sodium hydroxide in DMF  
• NaH or KH in DMF39  
All these methods have been proven to provide excellent yields of N-alkylated products. But 
they are also associated with several limitations. Most of them involve the usage of hazardous 
and carcinogenic aprotic solvents. After completion of reactions, these may lead to production of 
waste side products, which make purification difficult. Some of these possess pungent odors, 
which make working with them difficult.  
Therefore in order to accomplish an effective and environmental friendly reaction, 
potassium carbonate was chosen as the base. The reaction was complete in 3 hours but there 
were a number of side products observed as multiple close spots on TLC. Isolation of the final 
product was tricky as the TLC from column gave very dilute spots, which were extremely 
difficult to visualize. Purification was tried in many solvent systems like chloroform/methanol, 
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100% chloroform, DCM/methanol, 100% DCM other than the conventional EtOAc/Hex but 
none were very successful. A wide variety of stains were tried for visualization with no fruitful 
outcome. The reason for this problem is not understood. In order to avoid this problem, NaH 
60% dispersion in mineral oil, which is stronger base, was used instead which gave better 
separation of the final N-alkylated product. 
For the synthesis of the spirobenzisofuran moiety, several synthetic procedures are listed 
in literature. 2-Bromo-benzenemethanol with N-benzyl piperidone when used as starting material 
gave the final product with 75% yield.40 An established method makes use of the magnesium 
derivative of 2-(2-bromophenyl)-4,4-dimethyloxazoline with N-alkyl piperidones or N-phenyl 
piperidones which produces piperidinols which on subsequent hydrolysis produces the 
phthalides.41 Analysis of the side products of the Grignard reaction showed the presence of 
starting piperidones and substituted phenyloxazolines suggesting that piperidones undergoing 
enolization is the primary competing reaction by the Grignard’s reagents.42  
A more effective technique was to utilize lithium aryls that are reactive to carbonyl 
additions but not to enolizations.43 It has been established that a reaction of 2-lithio-N-
phenylbenzamide prepared by Hausner’s technique with the substituted piperidone followed by 
acidic workup led to phthalides in moderate yields (50%).44 This approach was utilized as it is 
versatile, faster and higher yielding.45 Overview of the technique is illustrated in Figure 17. 
This is an anhydrous reaction so all the needed apparatus was taken dry and all the 
reagents and reaction mixture was maintained dry using argon during the course of the reaction. 
Since organo-lithium compounds are hazardous to work with, so extreme care was taken while 
handling n-BuLi and isopropanol was always kept on side since it has deactivating effect to n-
BuLi.   
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                                     Figure 17: Hausner’s technique 
The reduction of the ketone group in the phthalide was reduced using BH3-THF. The 
borane helps make the ketone more susceptible to nucleophilic attack by the H- from another 
molecule of borane. 
For the final step alkylation of the spirobenzisofuran nitrogen, potassium carbonate was 
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obtained from column gave extremely dilute spots making the visualization of the product 
problematic. To overcome this, purification by preparative TLC was tried. A distinct band was 
observed for the final compound on the prep plate, which was then scraped off and the resulting 
silica was washed with a polar solvent system (95% EtOAc and 5% MeOH) and the solvent 
dried to get the final compound. Since methanol has a tendency to dissolve silica, therefore the 
concentrated product has silica present in it. This was then dissolved in solvent and filtered using 
the 0.5 micron millipore filter and dried again. Using this technique, the isolation of the final 
product was achieved in good purity but the yields were lowered due to several filtrations. 
In order to maximize yields, the solutions to the challenges with column chromatography 
were sought. After trying several different solvent systems (100% chloroform, chloroform with 
methanol, petroleum ether with hexane, 100% dichlomethane) different sizes of column, 
methods of packing the product onto the column (dry packing v/s wet packing), solvent gradient 
(from highly non polar to highly polar with ammonia), the purification of the final product was 
possible with good yields.  
After purification of the total six final compounds and their characterization by NMR, 
High Res. Mass and HPLC, the first three compounds were sent for their binding affinity 
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Most of these compounds show good to moderate binding to sigma receptors but these 
compounds did not exhibit sigma receptor selectivity. Compounds SA113 and SA115 had poor 
DAT binding. As expected, the analogue with two-carbon chain between the bezimidazolone and 
the spiribenzisofuran moieties was more selective to sigma-1 (Compound SA115 was 3-fold 
more selective for sigma-1 than sigma-2). As the chain length is increased the sigma-1 selectivity 
starts diminishing (as evident by compounds SA113 and SA114). Out of these three, compound 
SA114 showed moderate binding to DAT and a very tight binding for sigma-2 but did not show 
selectivity for sigma-1 (was 2-fold more selective for sigma-2). 
None of these compounds showed sigma-1 selectivity or good DAT binding profile. 
These compounds were good mixed affinity sigma ligands. 
Conclusions and future directions: 
The underlying principle of this project was to carry out dual targeting of sigma-1 
receptor and DAT to develop potential lead compounds for anti-cocaine therapy. Synthesis of 
analogues of our in house compound, CM699 that showed a good binding profile for both DAT 
and sigma-1, was undertaken. The lower benzimidazolone and top spirobenzisofuran moieties 
were kept the same and the spacer length was modified in the six synthetic analogues. These 
compounds were tested for their binding affinities at both DAT and sigma receptors. The first 
three tested compounds were shown to be mixed sigma antagonists and none of the compounds 
showed favorable DAT binding.  
In order to improve the binding profile, various modifications on the parent compound 
can be carried out. Effects of various fluorine substitutions on the benzene ring systems of 
benzimidazolone and spirobenzisofuran should be studied. Branching and substitutions on the 
linker chain is also a possibility. 
 





Reagents and starting materials were obtained from commercial suppliers and were used without 
purification. Precoated silica gel 60 F254 aluminum backed plates from Merck were used for thin-
layer chromatography (TLC). Column chromatography was performed on silica gel 60(Sorbent 
Technologies). 1H and 13C NMR spectra were obtained on a Bruker APX400 AT 400 and 100 
MHz, respectively. The high-resolution mass spectra (HRMS) were recorded on a Bruker 
microTOF mass spectrometer with an Electrospray ionization. The mass spectra (MS) were 
recorded on a Waters Aquity Ultra Performance LC with ZQ detector in ESI mode. Analytical 
HPLC was performed on an automated Waters Alliance system equipped with a Xterra® C18 
RP18 (4.6 × 100 mm i. d., 3.5µm) column or Xterra® C8 RP8 (4.6 × 100 mm i. d., 3.5µm), with 
a flow rate of 1ml/min ; λmax = 254 nm; mobile phase A: CH3CN and mobile phase B:H2O (0.2% 
triethylamine) linear gradient in 12 min. Chemical names were generated by ChemDraw Ultra 
(CambridgeSoft, version 12.0) . The overall yields, 1H and 13C NMR data for final compounds 
are reported in its free base form. 
Synthesis of Analogues: 
1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (SA103). 1-fluoro-2-nitrobenzene (2g) and 
methylamine (6ml) were refluxed for half an hour in 10ml MeOH to yield  N-methyl-2-
nitroaniline (SA100). After completion, the solvent was dried off and the product was 
concentrated. The next step was carried out by adding this product in the hydrogenation 
apparatus with Pd/C (300mg) for 3 hours, in 20 ml MeOH to give N1-methylbenzene-1,2-
diamine (SA101). After hydrogenation is complete, MeOH was dried off under Argon and the 
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product is stored under argon till next step is carried out. The final product was obtained by 
coupling with CDI ( 300mg) in 30ml dry freshly distilled THF. The solvent is evaporated under 
reduced pressure and the product was purified by column chromatography over silica gel using 
DCM : MeOH (9.5:0.5) to give 700mg of  1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one as 
white crystals. 1H NMR (400 MHz, DMSO) δ 7.05 (d, J = 6.5 Hz, 1H), 6.98 (ddt, J = 8.6, 5.0, 
2.4 Hz, 1H), 4.09 (q, J = 5.2 Hz, 1H), 3.26 (s, 1H), 3.16 (d, J = 5.2 Hz, 2H). 
13C NMR (101 MHz, DMSO) δ 154.84, 131.38, 128.64, 121.23, 120.90, 108.99, 107.97, 49.04, 
26.79. MS (ESI) m/z 149.41 [M+ +H] 
1'-benzyl-3H-spiro[isobenzofuran-1,4'-piperidin]-3-one (SA104). Bromobenzoic acid (10g) 
was dissolved in approximately 80 ml of freshly distilled THF and maintained at -78 deg C by 
dry ice, to this 2.5 M n-BuLi (36 ml) was added drop-wise for 30 minutes maintaining the 
temperature at -78oC. To this mixture, 1-benzylpiperidin-4-one (10g) dissolved in 40 ml dry 
THF, was added dropwise. This mixture was stirred at -78oC for another 30 minutes and then the 
reaction was allowed to continue overnight. Next, the mixture was quenched with 40 ml water 
and washed with 40 ml diethylether. The aqueous layer was separated and refluxed for an hour. 
It was then acidified to pH 2.5. The mixture was then extracted with DCM, washed with brine 
and dried over sodium sulphate. The solvent was then dried over reduced pressure to yield 20 ml 
of 1'-benzyl-3H-spiro[isobenzofuran-1,4'-piperidin]-3-one as a yellow oil.   1H NMR (400 MHz, 
DMSO) δ 7.94 (d, J = 7.6 Hz, 1H), 7.90-7.61 (m, 3H), 7.61-7.45 (m, 2H), 7.52 -7.14 (m, 2H), 
4.45 (s, 2H), 3.57 (d, J = 6.0 Hz, 1H), 3.40 (s, 1H), 3.26 (s, 1H), 2.81 (s, 2H), 2.49 (s, 1H), 1.92 
(d, J = 14.5 Hz, 1H). 13C NMR (101 MHz, DMSO) δ 152.26, 135.40, 134.18, 133.24, 132.90, 
131.84, 131.23,130.46, 130.39, 129.85, 129.70, 128.10, 125.96, 125.15, , 82.13, 67.45, 48.24, 
42.35, 39.56. MS (ESI) m/z 295.65 [M+ +H] 
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3H-spiro[isobenzofuran-1,4'-piperidine] (SA106). 1'-benzyl-3H-spiro[isobenzofuran-1,4'-
piperidin]-3-one was dissolved in dry THF and stirred for 15 minutes. The reaction mixture was 
brought to 0oC and borane in THF was added to it with continuous stirring. The reaction mixture 
was left on reflux overnight. Then it was acidified with 10% HCl (brought to pH 2) and refluxed 
for 4 hours followed by quenching with 2N NaOH (brought to pH 10). The solvent was 
evaporated on rotavap to yield 1'-benzyl-3H-spiro[isobenzofuran-1,4'-piperidine] as a white 
solid. The final step hydrogenation was carried out using Pd/C (500mg) in 100 ml MeOH to give 
the final product 3H-spiro[isobenzofuran-1,4'-piperidine] as a white powder. 1H NMR (400 
MHz, DMSO) δ 7.31 (d, J = 4.4 Hz, 1H), 5.01 (s, 1H), 4.49 (dt, 3H), 3.52 (d, J = 88.6 Hz, 2H), 
3.24 (s, 1H), 2.49 (dt, J = 3.7, 1.9 Hz, 3H), 2.18-1.83 (m, 3H). 13C NMR (101 MHz, DMSO) δ 
153.65, 142.97, 139.02, 128.46, 126.85, 82.82, 63.33, 56.47, 45.92, 41.25, 33.56, 19.01. MS 
(ESI) m/z 190.47 [M+ +H] 
1-(2-bromoethyl)-3-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (SA107).  To 1-methyl-
1,3-dihydro-2H-benzo[d]imidazol-2-one (SA103)(500 mg),  NaH (113.40 mg, 3.3747mmol) was 
added and it was stirred for 10 minutes at 0oC under argon and then at room temperature. After 
10 minutes, 1,2-dibromoethane (2.5 ml, 16.8734 mmol) was added and reaction mixture stirred 
for 45 minutes. After completion, the solvent was evaporated under reduced pressure and 
purification was carried out using column chromatography using silica gel, Hex: EtOAc (4:6) to 
give 400 mg of 1-(2-bromoethyl)-3-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one as a yellow 
oil. 1H NMR (400 MHz, DMSO) δ 8.20 (s, 1H), 7.88 (dd, J = 8.4, 1.5 Hz, 1H), 7.17 (d, J = 8.4 
Hz, 1H), 3.34 (s, 1H), 2.98 (q, J = 7.2 Hz, 2H), 2.57 – 2.31 (m, 1H), 1.06 (t, J = 7.2 Hz, 4H) 13C 
NMR (101 MHz, DMSO) δ 199.12, 170.90, 140.59, 131.78, 127.20, 124.14, 123.51, 111.63, 
31.38, 8.67. MS (ESI) m/z 255.87 [M+ +H] 
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1-(3-bromopropyl)-3-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (SA108). To 1-methyl-
1,3-dihydro-2H-benzo[d]imidazol-2-one (SA103)(500 mg),  NaH (113.40 mg, 3.3747 mmol) 
was added and it was stirred for 10 minutes at 0oC under argon and then at room temperature. 
After 10 minutes, 1,3-dibromopropane (3 ml, 15.8679 mmol) was added and reaction mixture 
stirred for 45 minutes. After completion, the solvent was evaporated under reduced pressure and 
purification was carried out using column chromatography using silica gel, Hex: EtOAc (4:6) to 
give 470 mg of 1-(3-bromopropyl)-3-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one one as a 
yellow oil. 1H NMR (400 MHz, DMSO) δ 11.74 (s, 1H), 7.36 (s, 1H), 7.26 – 6.72 (m, 2H), 3.32 
(s, 1H), 2.57 – 2.31 (m, 3H), 1.55 (q, J = 7.4 Hz, 2H), 0.86 (t, J = 7.3 Hz, 3H). 13C NMR (101 
MHz, DMSO) δ 170.40, 137.12, 134.66, 127.02, 123.66, 122.58, 111.66, 37.29, 24.71, 13.98. 
MS (ESI) m/z 269.34 [M+ +H] 
1-(5-bromopentyl)-3-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (SA109). To 1-methyl-
1,3-dihydro-2H-benzo[d]imidazol-2-one (SA103)(500 mg),  NaH (113.40 mg, 3.3747 mmol) 
was added and it was stirred for 10 minutes at 0oC under argon and then at room temperature. 
After 10 minutes, 1,5-dibromopentane (2 ml, 12.6578 mmol) was added and reaction mixture 
stirred for 45 minutes. After completion, the solvent was evaporated under reduced pressure and 
purification was carried out using column chromatography using silica gel, Hex: EtOAc (4:6) to 
give 600 mg of 1-(5-bromopentyl)-3-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one one as a 
yellow oil. 1H NMR (400 MHz, DMSO) δ 8.10 (s, 1H), 7.76 (dd, J = 8.4, 2.3 Hz, 1H), 7.17 (d, J 
= 7.5 Hz, 1H), 3.34 (s, 1H), 2.87 (q, J = 8.2 Hz, 2H), 2.34 – 2.22 (m, 1H), 1.02 (t, J = 7.2 Hz, 
4H) 13C NMR (101 MHz, DMSO) δ 198.65, 160.90, 140.59, 129.18, 126.256, 123.14, 121.22, 
101.63, 34.38, 18.68. MS (ESI) m/z 297.40 [M+ +H] 
1-(6-bromohexyl)-3-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (SA110). To 1-methyl-
1,3-dihydro-2H-benzo[d]imidazol-2-one (SA103)(500 mg),  NaH (113.40 mg, 3.3747 mmol) 
	   36	  
was added and it was stirred for 10 minutes at 0oC under argon and then at room temperature. 
After 10 minutes, 1,6-dibromohexane (4.2 ml, 17.6234 mmol) was added and reaction mixture 
stirred for 45 minutes. After completion, the solvent was evaporated under reduced pressure and 
purification was carried out using column chromatography using silica gel, Hex: EtOAc (4:6) to 
give 445 mg of 1-(6-bromohexyl)-3-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one as a yellow 
oil. 1H NMR (400 MHz, CDCl3) δ 7.27 (s, 2H), 7.17 – 7.02 (m, 1H), 7.04 – 6.89 (m, 1H), 3.89 (t, 
J = 7.2 Hz, 2H), 3.58 – 3.18 (m, 4H), 2.05 (s, 1H), 1.92 – 1.67 (m, 4H), 1.57 – 1.36 (m, 3H), 
1.27 (d, J = 7.1 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 154.42, 130.06, 129.34, 121.12, 121.04, 
107.48, 107.41, 40.99, 33.74, 32.57, 28.29, 27.80, 27.10, 25.98. MS (ESI) m/z 311.27 [M+ +H] 
1-(4-bromobut-2-en-1-yl)-3-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (SA111). To 1-
methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (SA103)(500 mg),  NaH (113.40 mg, 3.3747 
mmol) was added and it was stirred for 10 minutes at 0oC under argon and then at room 
temperature. After 10 minutes, 1,4-dibromobut-2-ene (2.5 ml, 14.2474 mmol) was added and 
reaction mixture stirred for 45 minutes. After completion, the solvent was evaporated under 
reduced pressure and purification was carried out using column chromatography using silica gel, 
Hex: EtOAc (3:7) to give 335 mg of 1-(4-bromobut-2-en-1-yl)-3-methyl-1,3-dihydro-2H-
benzo[d]imidazol-2-one as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.36 (s, 1H), 7.17 – 7.02 
(m, 1H), 7.01 – 6.43 (m, 1H), 3.43 (t, J = 7.2 Hz, 1H), 3.73 – 3.28 (m, 4H), 2.23 (s, 1H), 1.87 – 
1.27 (m, 2H), 1.45 – 1.25 (m, 2H), 1.17 (d, J = 6.8 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 
156.41, 131.56, 121.222, 121.04, 107.41, 41.96, 33.75, 32.62, 27.79, 26.70, 25.60, 24.68. MS 
(ESI) m/z 295.34 [M+ +H] 
1-(4-bromopentyl)-3-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (SA112). To 1-methyl-
1,3-dihydro-2H-benzo[d]imidazol-2-one (SA103)(500 mg),  NaH (113.40 mg, 3.3747 mmol) 
was added and it was stirred for 10 minutes at 0oC under argon and then at room temperature. 
	   37	  
After 10 minutes, 1,4-dibromopentane (3.2 ml, 15.3498 mmol) was added and reaction mixture 
stirred for 45 minutes. After completion, the solvent was evaporated under reduced pressure and 
purification was carried out using column chromatography using silica gel, Hex: EtOAc (4:6) to 
give 525 mg of 1-(6-bromohexyl)-3-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one as a yellow 
oil. 1H NMR (400 MHz, CDCl3) δ 7.45 (s, 1H), 7.12 – 7.07 (m, 1H), 7.14 – 6.19 (m, 1H), 3.56 (t, 
J = 7.3 Hz, 1H), 3.73 – 3.28 (m, 4H), 2.15 (s, 1H), 1.79 – 1.53 (s, 1H), 1.43 – 1.33 (s, 1H). 13C 
NMR (101 MHz, CDCl3) δ 154.32, 133.54, 123.24, 120.14, 103.23, 40.33, 32.25, 26.87, 26.23, 
25.80. MS (ESI) m/z 297.41 [M+ +H] 
1-(3-(3H-spiro[isobenzofuran-1,4'-piperidin]-1'-yl)propyl)-3-methyl-1,3-dihydro-2H-
benzo[d]imidazol-2-one (SA113)A mixture of SA108 (80mg,0.2972 mmol), SA 106 (112.50 
mg,0.5944 mmol) and K2CO3(123.24 mg, 0.89172 mmol) in DMF(2ml) was vigorously stirred 
for 3 hours. After completion, the solvent was evaporated off and concentrated product was 
purified using column chromatography on silica using Hex:EtOAc (5:5) to give 45 mg of whitish 
yellow powder. 1H NMR (400 MHz, CDCl3) δ 8.02 (s, 1H), 7.27 (t, J = 3.9 Hz, 2H), 7.20 (d, J = 
5.1 Hz, 1H), 7.19 – 7.04 (m, 3H), 7.03 – 6.89 (m, 1H), 5.05 (s, 1H), 3.99 (t, J = 6.9 Hz, 2H), 3.61 
– 3.48 (m, 1H), 3.44 (d, J = 8.7 Hz, 2H), 2.93 (dd, J = 28.7, 9.1 Hz, 6H), 2.51 (d, J = 7.2 Hz, 
2H), 2.42 (d, J = 11.4 Hz, 1H), 2.01 (dd, J = 14.2, 7.3 Hz, 3H), 1.76 (d, J = 13.6 Hz, 1H), 1.26 (s, 
1H) 13C NMR (101 MHz, CDCl3) δ 162.49, 154.42, 138.90, 130.04, 129.53, 127.57, 127.32, 
121.10, 121.04, 120.79, 107.68, 107.33, 84.56, 70.71, 55.59, 50.08, 39.35, 36.45, 31.41, 27.09, 
25.79. HRMS m/z 377.2103 (Cal), found 378.2270 [M+ +H]. 
1-(6-(3H-spiro[isobenzofuran-1,4'-piperidin]-1'-yl)hexyl)-3-methyl-1,3-dihydro-2H-
benzo[d]imidazol-2-one (SA114). A mixture of SA110 (80mg, 0.2570 mmol), SA 106 (87.56 
mg, 0.4626 mmol) and K2CO3 (123.24 mg, 0.89172 mmol) in DMF (2ml) was vigorously stirred 
for 3 hours. After completion, the solvent was evaporated off and concentrated product was 
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purified using column chromatography on silica using Hex:EtOAc (6:4) to give 55 mg of whitish 
yellow powder. 1H NMR (400 MHz, Chloroform-d) δ 7.22 (dd, J = 10.0, 6.3 Hz, 1H), 7.15 – 
6.97 (m, 1H), 6.96 (d, J = 4.4 Hz, 0H), 5.02 (s, 1H), 3.84 (t, J = 7.0 Hz, 1H), 3.71 – 3.24 (m, 
14H), 3.20 – 3.08 (m, 1H), 2.67 (dt, J = 26.5, 10.4 Hz, 2H), 2.29 (dd, J = 13.7, 4.4 Hz, 1H), 1.92 
– 1.56 (m, 3H), 1.56 – 1.26 (m, 2H), 1.21 (s, 1H), 0.82 (d, J = 7.7 Hz, 0H). 
13C NMR (101 MHz, CDCl3) ? 154.14, 144.45, 138.49, 130.32, 129.92, 128.86, 127.83, 127.51, 
127.17, 121.44, 121.35, 121.01, 120.85, 108.13, 107.59, 83.63, 77.53, 77.21, 76.89, 70.86, 59.47, 
50.11, 49.54, 35.33, 29.62, 27.11. HRMS m/z 419.2573 (Cal), found 420.2746 [M+ +H].	  
13	  –	  4. 1-(2-(3H-spiro[isobenzofuran-1,4'-piperidin]-1'-yl)ethyl)-3-methyl-1,3-dihydro-2H-
benzo[d]imidazol-2-one (SA115). A mixture of SA107  (80mg, 0.3135 mmol), SA 106 (94.78 
mg, 0.5017 mmol) and K2CO3 (123.24 mg, 0.89172 mmol) in DMF(2ml) was vigorously stirred 
for 3 hours. After completion, the solvent was evaporated off and concentrated product was 
purified using column chromatography on silica using Hex:EtOAc (6:4) to give 25 mg of whitish 
yellow powder. 1H NMR (400 MHz, CDCl3) δ 7.27 (dd, J = 5.7, 2.9 Hz, 2H), 7.16 – 7.02 (m, 
4H), 6.99 (dd, J = 5.5, 3.3 Hz, 1H), 5.07 (s, 2H), 4.00 (m, 2H), 3.43 (s, 3H), 2.96 (d, J = 10.9 Hz, 
2H), 2.83 – 2.69 (m, 2H), 2.57 (s, 2H), 2.28 (s, 1H), 1.99 (td, J = 13.2, 4.5 Hz, 2H), 1.78 (d, J = 
11.9 Hz, 2H).   13C NMR (101 MHz, CDCl3) δ 154.36, 145.52, 138.90, 136.37, 130.10, 129.38, 
127.59, 127.33, 121.18, 121.14, 121.05, 120.79, 107.64, 107.46, 84.47, 70.72, 56.15, 50.40, 
38.96, 36.52, 27.13. HRMS m/z 363.1947 (Cal), found 364.2155 [M+ +H]. 
1-(5-(3H-spiro[isobenzofuran-1,4'-piperidin]-1'-yl)pentyl)-3-methyl-1,3-dihydro-2H-
benzo[d]imidazol-2-one (SA116) A mixture of SA109  (80mg, 0.2691 mmol), SA 106 (94.78 
mg, 0.5383 mmol) and K2CO3 (123.24 mg, 0.89172 mmol) in DMF(2ml) was vigorously stirred 
for 3 hours. After completion, the solvent was evaporated off and concentrated product was 
purified using column chromatography on silica using Hex:EtOAc (6:4) to give 25 mg of whitish 
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yellow powder. 1H NMR (400 MHz, CDCl3) δ 7.25 (d, J = 23.4 Hz, 5H), 7.00 (s, 4H), 5.07 (s, 
2H), 3.91 (s, 1H), 3.43 (s, 3H), 3.19 (s, 1H), 2.74 (d, J = 33.9 Hz, 3H), 2.38 (s, 2H), 1.82 (d, J = 
13.3 Hz, 5H), 1.34 (d, J = 66.8 Hz, 5H), 0.88 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 154.46, 
144.16, 138.47, 130.03, 129.24, 127.99, 127.65, 121.23, 121.13, 121.05, 107.54, 107.44, 83.42, 
71.05, 57.82, 49.67, 40.75, 34.92, 29.69, 28.07, 27.12, 24.76, 24.41, 14.11. HRMS m/z 405.2456 
(Cal), found 428.2416 [M+ +Na]. 
1-(4-(3H-spiro[isobenzofuran-1,4'-piperidin]-1'-yl)pentyl)-3-methyl-1,3-dihydro-2H-
benzo[d]imidazol-2-one (SA117). A mixture of SA112 (80mg, 2691 mmol), SA 106 (94.78 mg, 
0.5383 mmol) and K2CO3 (123.24 mg, 0.89172 mmol) in DMF (2ml) was vigorously stirred for 
3 hours. After completion, the solvent was evaporated off and concentrated product was purified 
using column chromatography on silica using Hex:EtOAc (6:4) to give 40 mg of whitish yellow 
powder. 1H NMR (400 MHz, CDCl3) δ 7.27 (d, J = 4.2 Hz, 3H), 7.17 – 7.05 (m, 3H), 6.99 (d, J 
= 4.2 Hz, 1H), 5.07 (s, 2H), 3.92 (d, J = 6.6 Hz, 2H), 3.43 (s, 3H), 2.72 (s, 3H), 2.61 (d, J = 12.0 
Hz, 1H), 2.08 – 1.91 (m, 2H), 1.90 – 1.65 (m, 5H), 1.44 (dd, J = 13.3, 7.3 Hz, 1H), 1.26 (s, 1H), 
1.05 (d, J = 6.3 Hz, 3H), 0.93 (s, 1H). 13C NMR (101 MHz, CDCl3) δ 154.40, 145.63, 138.83, 
130.09, 129.37, 127.52, 127.32, 121.09, 121.02, 121.00, 120.89, 107.60, 107.40, 85.05, 70.74, 
59.16, 47.27, 42.72, 41.21, 36.96, 36.75, 30.77, 27.11, 25.82, 13.82. HRMS m/z 405.2456 (Cal), 
found 428.2479[M+ +Na]. 
1-(4-(3H-spiro[isobenzofuran-1,4'-piperidin]-1'-yl)but-2-en-1-yl)-3-methyl-1,3-dihydro-2H-
benzo[d]imidazol-2-one (SA118). A mixture of SA111 (80mg, 2691 mmol), SA 106 (94.78 mg, 
0.5383 mmol) and K2CO3 (123.24 mg, 0.89172 mmol) in DMF (2ml) was vigorously stirred for 
3 hours. After completion, the solvent was evaporated off and concentrated product was purified 
using column chromatography on silica using Hex:EtOAc (6:4) to give 40 mg of whitish yellow 
powder. 1H NMR (400 MHz, Chloroform-d) δ 7.37-7.22 (m, 1H), 7.19 (d, J = 3.4 Hz, 1H), 7.08 
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(d, J = 2.3 Hz, 0H), 7.01-6.85 (m, 3H), 5.93 -5.62 (m, 1H), 5.05 (s, 1H), 4.55 (d, J = 4.6 Hz, 1H), 
3.57-3.32 (m, 5H), 3.22 (d, J = 5.8 Hz, 1H), 3.01 (d, J = 12.2 Hz, 1H), 2.68-2.45 (m, 1H), 2.22-
2.03 (m, 1H), 2.03 (s, 1H), 1.88-1.61 (m, 1H), 1.26 (s, 1H). 13C NMR (101 MHz, CDCl3) δ 
154.46, 144.15, 138.47, 130.03, 129.24, 127.99, 127.65, 121.23, 121.13, 121.06, 107.54, 107.44, 
83.41, 71.05, 57.82, 40.75, 34.92, 29.69, 28.07, 27.12, 24.41, 22.67. HRMS m/z 389.2103 (Cal), 
found 390.2222 [M+ +H]. 
Binding affinity assays: 
Dopamine Transporter Binding 
 
Brains from male Sprague-Dawley rats weighing 200-225 g (Bioreclamation) were removed, 
striatum dissected and quickly frozen. Membranes were prepared by homogenizing tissues in 20 
volumes (w/v) of ice cold modified sucrose phosphate buffer (0.32M sucrose, 7.74 mM 
Na2HPO4, 2.26 mM NaH2PO4, pH adjusted to 7.4) using a Brinkman Polytron (setting 6 for 20 
sec.) and centrifuged at 50,000 x g for 10 min at 4°C.  The resulting pellet was resuspended in 
buffer, recentrifuged and resuspended in buffer to a concentration of 10 mg/ml. Ligand binding 
experiments were conducted in assay tubes containing 0.5 ml sucrose phosphate buffer for 120 
min on ice. Each tube contained 0.5nM 3H WIN 35428 (specific activity 76 Ci/mmol, 
PerkinElmer Life Sciences, MA) and 1.0 mg striatal tissue (original wet weight).  Nonspecific 
binding was determined using 0.1 mM cocaine HCl (Sigma).  Incubations were terminated by 
rapid filtration through Whatman GF/B filters, presoaked in 0.05% PEI (polyethyleneimine), 
using a Brandel R48 filtering manifold (Brandel Instruments Gaithersburg, Maryland). The 
filters were washed twice with 5ml cold buffer and transferred to scintillation vials. Cytoscint 
(MP Biomedicals, OH ) (3.0ml) was added and the vials were counted the next day using a 
Perkin Elmer Tri-Carb 2910 liquid scintillation counter (Perkin Elmer Life Sciences, MA). Data 
were analyzed by using GraphPad Prism software (San Diego, California). 
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Sigma 1 Receptor Binding 
Frozen whole guinea pig brains (minus cerebellum) were thawed on ice weighed and 
homogenized (with a glass and teflon apparatus) in 10 mM Tris-HCl with 0.32 M sucrose pH 7.4 
(10 ml/gm tissue). The homogenate was centrifuged at 800 x g for 10 min at 4° C. The 
supernatant was collected into a clean centrifuge tube the remaining pellet was re-suspended by 
vortex in 10 ml buffer (tissue) and re-spun at 12,500 x g for 10 min at 4° C. The supernatants 
were pooled and spun at 28,000 x g for 15 min at 4° C. The supernatant was discarded and the 
remaining pellet was resuspended at 3ml/gram (original wet weight; O.W.W.) in 10 mM Tris-
HCl with 0.32 M sucrose, pH 7.4 and mixed by vortexing. The tissue suspension was incubated 
at 25° C (water bath) for 15 minutes. The tissue was then re-spun at 28,000 x g for 15 minutes. 
The supernatant was poured off and the pellet was gently re-suspended in experimental buffer to 
80 mg/ml (O.W.W). 
Ligand binding experiments were conducted in polypropylene assay tubes containing 0.5 ml of 
50 mM Tris-HCl  buffer,  pH 8.0 for 120 minutes at room temperature. Each tube contained 3 
nM 3H Pentazocine (specific activity 28 Ci/mmol, Perkin Elmer Life Science) and 8.0 mg tissue 
(O.W.W.).  Nonspecific binding was determined using 10 µM haloperidol. Incubations were 
terminated by rapid filtration through Whatman GF/B filters, presoaked in 0.3% PEI 
(polyethylenimine), using a Brandel R48 filtering manifold (Brandel Instruments Gaithersburg, 
Maryland). The filters were washed twice with 5ml cold buffer (10 mM Tris-HCl, pH 8.0) and 
transferred to scintillation vials. Cytoscint (MP Biomedicals, OH)  (3.0ml) was added and the 
vials were counted the next day using a Tri Carb 2910 liquid scintillation counter (Perkin Elmer 
Life Sciences, MA). Data were analyzed by using GraphPad Prism software (San Diego, CA).  
Sigma 2 Receptor Binding 
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Frozen whole guinea pig brains (minus cerebellum) were thawed on ice weighed and 
homogenized (with a glass and teflon apparatus) in 10 mM Tris-HCl with 0.32 M sucrose pH 7.4 
(10 ml/gm tissue). The homogenate was centrifuged at 800 x g for 10 min at 4° C. The 
supernatant was collected into a clean centrifuge tube the remaining pellet was re-suspended by 
vortex in 10 ml buffer (tissue) and re-spun at 12,500 x g for 10 min at 4° C. The supernatants 
were pooled and spun at 28,000 x g for 15 min at 4° C. The supernatant was discarded and the 
remaining pellet was resuspended at 3ml/gram (original wet weight; O.W.W.) in 10 mM Tris-
HCl with 0.32 M sucrose, pH 7.4 and mixed by vortexing. The tissue suspension was incubated 
at 25° C (water bath) for 15 minutes. The tissue was then re-spun at 28,000 x g for 15 minutes. 
The supernatant was poured off and the pellet was gently re-suspended in experimental buffer to 
80 mg/ml (O.W.W). 
Ligand binding experiments were conducted in polypropylene assay tubes containing 0.5 ml of 
50 mM Tris-HCl  buffer,  pH 8.0 for 120 minutes at room temperature. Each tube contained 3 
nM 3H DTG (specific activity 48 Ci/mmol, Perkin Elmer Life Science, MA), 200 nM (+) 
pentazocine (Sigma Aldrich, MO) and 8.0 mg tissue (O.W.W.).  Nonspecific binding was 
determined using 100 µM haloperidol. Incubations were terminated by rapid filtration through 
Whatman GF/B filters, presoaked in 0.3% PEI (polyethylenimine), using a Brandel R48 filtering 
manifold (Brandel Instruments Gaithersburg, Maryland). The filters were washed twice with 5ml 
cold buffer (10 mM Tris-HCl, pH 8.0) and transferred to scintillation vials. Cytoscint (MP 
Biomedicals, OH)  (3.0ml) was added and the vials were counted the next day using a Tri Carb 
2910 liquid scintillation counter (Perkin Elmer Life Sciences, MA). Data were analyzed by using 
GraphPad Prism software (San Diego, CA). 
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